AA Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206).

Trial Profile

AA Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs AFM 13 (Primary) ; Pembrolizumab
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Acronyms KEYNOTE- 206
  • Sponsors Affimed Therapeutics
  • Most Recent Events

    • 20 Mar 2018 According to an Affimed media release, treatment is the study is ongoing, and till now 24 patients have been treated. Complete 3 month data from the study is expected in mid -2018.
    • 01 Feb 2018 According to an Affimed media release, 21 patients have been enrolled in extension cohort of this trial.
    • 01 Feb 2018 Status changed from recruiting to active, no longer recruiting, as reported in an Affimed Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top